Mary S Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11635336/publications.pdf

Version: 2024-02-01

186265 233421 10,357 49 28 45 citations h-index g-index papers 50 50 50 14888 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	27.8	3,688
2	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 2012, 18, 883-891.	30.7	3,098
3	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 2020, 182, 1044-1061.e18.	28.9	691
4	Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2007, 25, 869-875.	1.6	266
5	Sentinel Lymph Node Biopsy in the Management of Patients With Primary Cutaneous Melanoma: Review of a Large Single-Institutional Experience With an Emphasis on Recurrence. Annals of Surgery, 2001, 233, 250-258.	4.2	217
6	Patterns of detection in patients with cutaneous melanoma. Cancer, 2000, 89, 342-347.	4.1	207
7	Cutaneous Desmoplastic Melanoma. American Journal of Surgical Pathology, 2004, 28, 1518-1525.	3.7	192
8	Sentinel Lymph Node Biopsy in Patients With Diagnostically Controversial Spitzoid Melanocytic Tumors. American Journal of Surgical Pathology, 2002, 26, 47-55.	3.7	168
9	Recurrence and Survival in Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma: Analysis of 153 Patients from a Single Institution. Annals of Surgical Oncology, 2011, 18, 2529-2537.	1.5	164
10	Five Hundred Patients With Merkel Cell Carcinoma Evaluated at a Single Institution. Annals of Surgery, 2011, 254, 465-475.	4.2	148
11	Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma. Annals of Surgical Oncology, 2006, 13, 302-309.	1.5	127
12	Prediction of Nonsentinel Lymph Node Status in Melanoma. Annals of Surgical Oncology, 2003, 10, 27-31.	1.5	126
13	Subungual melanoma: management considerations. American Journal of Surgery, 2008, 195, 244-248.	1.8	101
14	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
15	Utility of Preoperative [(18)]F Fluorodeoxyglucose–Positron Emission Tomography Scanning in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2006, 13, 525-532.	1.5	83
16	Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer, 2012, 118, 3311-3320.	4.1	81
17	A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity. Annals of Surgical Oncology, 2006, 13, 1123-1129.	1.5	77
18	Post-treatment sarcoma in breast cancer patients. Annals of Surgical Oncology, 1994, 1, 66-72.	1.5	68

#	Article	IF	Citations
19	Methods of Detection of First Recurrence in Patients with Stage I/II Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2008, 15, 2206-2214.	1.5	61
20	Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection. Annals of Surgical Oncology, 2001, 8, 328-337.	1.5	56
21	Yield and Predictors of Radiologic Studies for Identifying Distant Metastases in Melanoma Patients with a Positive Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2007, 14, 2133-2140.	1.5	56
22	Radiolocalization of the sentinel lymph node in Merkel cell carcinoma: A clinical analysis of seven cases., 1998, 67, 251-254.		55
23	Patterns of First-Recurrence and Post-recurrence Survival in Patients with Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2007, 14, 1934-1942.	1.5	47
24	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	1.5	47
25	Prognostic Implications of Multiple Lymphatic Basin Drainage in Patients With Truncal Melanoma. Journal of Clinical Oncology, 2005, 23, 518-524.	1.6	41
26	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 939-946.	1.5	41
27	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of Surgical Oncology, 2020, 27, 1180-1188.	1.5	39
28	Lymphatic mapping for Merkel cell carcinoma. Journal of the American Academy of Dermatology, 1997, 37, 650-651.	1.2	28
29	Current Management of Patients With Merkel Cell Carcinoma. Dermatologic Surgery, 2004, 30, 321-325.	0.8	28
30	Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Research, 2009, 19, 106-111.	1.2	26
31	PET Scanning with 18F 2-Fluoro-2-Deoxy-?-Glucose (FDG) in Patients with Melanoma Benefits and Limitations. Molecular Imaging and Biology, 1999, 2, 93-98.	0.3	25
32	Family Communication After Melanoma Diagnosis. Archives of Dermatology, 2008, 144, 553-4.	1.4	24
33	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. Journal of Surgical Oncology, 2014, 109, 405-409.	1.7	23
34	An Increased Number of Sentinel Lymph Nodes Is Associated with Advanced Breslow Depth and Lymphovascular Invasion in Patients with Primary Melanoma. Annals of Surgical Oncology, 2009, 16, 948-952.	1.5	19
35	Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland. Annals of Surgical Oncology, 2016, 23, 9001-9009.	1.5	18
36	Family Communication Patterns After Melanoma Diagnosis. Journal of Family Communication, 2009, 9, 209-232.	1.6	17

#	Article	IF	CITATIONS
37	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. Annals of Surgical Oncology, 2014, 21, 4324-4329.	1.5	13
38	Cutaneous melanoma in patients with sarcoma. , 1997, 79, 843-848.		12
39	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. Annals of Surgical Oncology, 2020, 27, 5248-5256.	1.5	12
40	Current Management of Patients With Merkel Cell Carcinoma. Dermatologic Surgery, 2004, 30, 321-325.	0.8	10
41	Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. Melanoma Research, 2013, 23, 40-46.	1.2	10
42	Lymphatic mapping in the management of melanoma in children Pediatric Dermatology, 1998, 15, 421-425.	0.9	6
43	Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection. Annals of Surgical Oncology, 2001, 8, 328-337.	1.5	5
44	ASO Author Reflections: Role of Sentinel Lymph Node Biopsy in T1b Melanoma. Annals of Surgical Oncology, 2020, 27, 5257-5258.	1.5	2
45	Sentinel Lymph Node Mapping in Patients With Cutaneous Melanoma. Dermatologic Surgery, 2004, 30, 272-278.	0.8	1
46	Myoepithelial carcinoma of the extremity: Response to isolated limb infusion. Journal of Surgical Oncology, 2015, 112, 510-513.	1.7	1
47	Sentinel Lymph Node Mapping in Patients With Cutaneous Melanoma. Dermatologic Surgery, 2004, 30, 272-278.	0.8	0
48	Advances in sentinel lymph node mapping for patients with melanoma. Future Oncology, 2012, 8, 191-203.	2.4	0
49	Lymph nodes and the melanoma surgeon: re-defining a long-term relationship. Melanoma Management, 2016, 3, 73-82.	0.5	O